Triazavirin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan |
k replaced: nampaknya → tampaknya |
||
| (20 revisi perantara oleh 2 pengguna tidak ditampilkan) | |||
Baris 1:
{{Drugbox
| IUPAC_name = 2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-7(4''H'')-one
Baris 7 ⟶ 6:
| tradename =
| legal_US = Investigational New Drug
| legal_status =
<!--Pharmacokinetic data-->
Baris 30 ⟶ 29:
}}
'''Triazavirin''' ('''TZV''', '''Riamilovir''') adalah antivirus analog [[nukleotida]] yang awalnya dikembangkan di Rusia yang telah menunjukkan kemanjuran terhadap [[influenza]] A dan B, termasuk strain [[H5n1|H5N1]].<ref>{{Cite journal|last=Kiselev|first=O. I.|last2=Deeva|first2=E. G.|last3=Mel'nikova|first3=T. I.|last4=Kozeletskaia|first4=K. N.|last5=Kiselev|first5=A. S.|last6=Rusinov|first6=V. L.|last7=Charushin|first7=V. N.|last8=Chupakhin|first8=O. N.|date=2012-11|title=[A new antiviral drug Triazavirin: results of phase II clinical trial]|url=https://www.ncbi.nlm.nih.gov/pubmed/23477247|journal=Voprosy Virusologii|volume=57|issue=6|pages=9–12|issn=0507-4088|pmid=23477247}}</ref><ref>{{Cite journal|last=Vincent|first=Martin J.|last2=Bergeron|first2=Eric|last3=Benjannet|first3=Suzanne|last4=Erickson|first4=Bobbie R.|last5=Rollin|first5=Pierre E.|last6=Ksiazek|first6=Thomas G.|last7=Seidah|first7=Nabil G.|last8=Nichol|first8=Stuart T.|date=2005-08-22|title=Chloroquine is a potent inhibitor of SARS coronavirus infection and spread|url=https://www.ncbi.nlm.nih.gov/pubmed/16115318|journal=Virology Journal|volume=2|pages=69|doi=10.1186/1743-422X-2-69|issn=1743-422X|pmc=1232869|pmid=16115318}}</ref><ref>{{Cite journal|last=Karpenko|first=Inna|last2=Deev|first2=Sergey|last3=Kiselev|first3=Oleg|last4=Charushin|first4=Valerey|last5=Rusinov|first5=Vladimir|last6=Ulomsky|first6=Eugeney|last7=Deeva|first7=Ella|last8=Yanvarev|first8=Dmitry|last9=Ivanov|first9=Alexander|date=2010-05|title=Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication|url=https://www.ncbi.nlm.nih.gov/pubmed/20194696|journal=Antimicrobial Agents and Chemotherapy|volume=54|issue=5|pages=2017–2022|doi=10.1128/AAC.01186-09|issn=1098-6596|pmc=2863629|pmid=20194696}}</ref><ref>{{Cite journal|last=Shvetsov|first=Alexey V.|last2=Zabrodskaya|first2=Yana A.|last3=Nekrasov|first3=Peter A.|last4=Egorov|first4=Vladimir V.|date=2018-07-27|title=Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure|url=https://doi.org/10.1080/07391102.2017.1367329|journal=Journal of Biomolecular Structure and Dynamics|volume=36|issue=10|pages=2694–2698|doi=10.1080/07391102.2017.1367329|issn=0739-1102|pmid=28828928}}</ref>
Menurut riset, {{PAGENAMEPURE}} tampaknya mampu mengurangi dampak dari penyakit flu dan juga komplikasi penyakit terkait.<ref>{{Cite web|url=https://www.rt.com/russia/480037-china-tests-russian-drug-coronavirus/|title=China tests Russian anti-viral drug which might treat coronavirus as Moscow warns of possible 'mass outbreak'|website=RT International|language=en|access-date=2020-04-20}}</ref>
Antivirus ini memiliki inti dari ''novel triazolotriazine,'' yang mewakili kelas struktural baru dari obat-obatan antivirus non-nukleosida.<ref name=":0">{{Cite journal|last=Rusinov|first=Vladimir L.|last2=Sapozhnikova|first2=Irina M.|last3=Ulomskii|first3=Evgeny N.|last4=Medvedeva|first4=Natalia R.|last5=Egorov|first5=Vladimir V.|last6=Kiselev|first6=Oleg I.|last7=Deeva|first7=Ella G.|last8=Vasin|first8=Andrey V.|last9=Chupakhin|first9=Oleg N.|date=2015-03-01|title=Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins|url=https://doi.org/10.1007/s10593-015-1695-4|journal=Chemistry of Heterocyclic Compounds|language=en |volume=51|issue=3|pages=275–280|doi=10.1007/s10593-015-1695-4|issn=1573-8353}}</ref>
==Manfaat==
Triazavirin pada mulanya dikembangkan di [[Akademi Ilmu Pengetahuan Rusia]], Universitas Federal Ural di [[Ekaterinburg]], [[Rusia]] yang dikembangkan untuk mengatasi wabah dari virus [[Flu burung|Flu Burung]] ([[H5N1]]), kemudian dikarenakan terdapat beberapa persamaan dengan [[koronavirus]], maka para peneliti merasa perlu untuk mencoba meneliti khasiat obatnya pada pasien korona.<ref name=":0" /><ref name=loginova>Loginova SIa, Borisevich SV, Maksimov VA, et al. Antibiot Khimioter. 2007;52(11-12):18‐20.</ref><ref name=":1">{{Cite web|url=https://pubmed.ncbi.nlm.nih.gov/19275052/|title=[Investigation of Triazavirin Antiviral Activity Against Influenza A Virus (H5N1) in Cell Culture]|last=SIa|first=Loginova|last2=Sv|first2=Borisevich|date=2007|website=Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]|language=en|pmid=19275052|access-date=2020-05-03|last3=Va|first3=Maksimov|last4=Vp|first4=Bondarev|last5=Sk|first5=Kotovskaia|last6=Vl|first6=Rusinov|last7=Vn|first7=Charushin}}</ref>
Sebagian besar penelitian dilakukan dalam rangka menguji aktivitas anti-infuenza.<ref name="loginova" /><ref name=":1" />
== Referensi ==
{{Reflist}}
| |||